menbutil süstelahus
animedica gmbh - menbutoon - süstelahus - 100mg 1ml 100ml 1tk
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - rinnanäärmed - antineoplastilised ained - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
mirador® forte
adama - emulsioonikontsentraat - asoksüstrobiin + tebukonasool - fungitsiidid
insulin human winthrop
sanofi-aventis deutschland gmbh - insulin human - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõbi, kus on vaja insuliiniravi. insuliini inimese winthrop kiire sobib ka millega kaasnes hüperglükeemiline kooma ja ketoatsidoos, samuti saavutada enne, intra - ja postoperatiivne stabiilsuse patsientidel, kellel.
banjo forte®
adama - suspensioonikontsentraat - dimetomorf + fluasinaam - fungitsiidid
kantik®
adama - emulsioonikontsentraat - fenpropidiin + prokloraas + tebukonasool - fungitsiidid